Evoke Pharma Gross Margin 2013-2025 | EVOK
Current and historical gross margin for Evoke Pharma (EVOK) over the last 10 years. The current gross profit margin for Evoke Pharma as of September 30, 2025 is %.
| Evoke Pharma Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2025-09-30 | $0.01B | $0.01B | 100.00% |
| 2025-06-30 | $0.01B | $0.01B | 100.00% |
| 2025-03-31 | $0.01B | $0.01B | 100.00% |
| 2024-12-31 | $0.01B | $0.01B | 100.00% |
| 2024-09-30 | $0.01B | $0.01B | 100.00% |
| 2024-06-30 | $0.01B | $0.01B | 100.00% |
| 2024-03-31 | $0.01B | $0.01B | 100.00% |
| 2023-12-31 | $0.01B | $0.01B | 100.00% |
| 2023-09-30 | $0.01B | $0.01B | 100.00% |
| 2023-06-30 | $0.00B | $0.00B | 100.00% |
| 2023-03-31 | $0.00B | $0.00B | 100.00% |
| 2022-12-31 | $0.00B | $0.00B | 100.00% |
| 2022-09-30 | $0.00B | $0.00B | 100.00% |
| 2022-06-30 | $0.00B | $0.00B | 100.00% |
| 2022-03-31 | $0.00B | $0.00B | 100.00% |
| 2021-12-31 | $0.00B | $0.00B | 100.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |